Sam Samad
Known title: Executive Vice President & CFOCIK: 0001694295
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Transaction History
| DGX | ▲ Buy | Grant | 102 | $21K | 7/22/2026 | View on chart |
| DGX | ▲ Buy | Grant | 108 | $21K | 4/20/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 7,720 | $1.6M | 3/4/2026 | View on chart |
| DGX | ▲ Buy | Grant | 13,947 | $2.9M | 3/4/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 869 | $178K | 3/2/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 855 | $180K | 2/18/2026 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 1,010 | $209K | 2/18/2026 | View on chart |
| DGX | ▲ Buy | Grant | 3,965 | $0 | 2/18/2026 | View on chart |
| DGX | ▲ Buy | Grant | 69 | $13K | 1/28/2026 | View on chart |
| DGX | ▲ Buy | Grant | 68 | $13K | 10/21/2025 | View on chart |
| DGX | ▼ Sell | Other | 72 | $12K | 7/21/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 850 | $144K | 7/16/2025 | View on chart |
| DGX | ▼ Sell | Other | 74 | $12K | 4/21/2025 | View on chart |
| DGX | ▲ Buy | Grant | 13,884 | $2.4M | 3/4/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 7,684 | $1.3M | 3/4/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 869 | $149K | 2/26/2025 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 1,031 | $175K | 2/19/2025 | View on chart |
| DGX | ▲ Buy | Grant | 4,538 | $0 | 2/12/2025 | View on chart |
| DGX | ▼ Sell | Other | 35 | $6K | 1/29/2025 | View on chart |
| DGX | ▼ Sell | Other | 37 | $6K | 10/21/2024 | View on chart |
| DGX | ▼ Sell | Other | 21 | $3K | 7/22/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 3,910 | $558K | 7/16/2024 | View on chart |
| DGX | ▲ Buy | Grant | 24 | $3K | 4/22/2024 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 656 | $83K | 2/28/2024 | View on chart |
| DGX | ▲ Buy | Grant | 5,478 | $0 | 2/14/2024 | View on chart |
| DGX | ▲ Buy | Grant | 17 | $2K | 1/31/2024 | View on chart |
| DGX | ▲ Buy | Grant | 18 | $2K | 10/23/2023 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 3,909 | $548K | 7/14/2023 | View on chart |
| DGX | ▲ Buy | Grant | 4,710 | $0 | 2/23/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 2,082 | $0 | 3/1/2022 | View on chart |
| ILMN | ▲ Buy | Option Exercise | 4,561 | $0 | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 1,808 | $578K | 2/22/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 723 | $295K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.